Skip to main content
. 2017 Jan 9;7:39604. doi: 10.1038/srep39604

Figure 5.

Figure 5

Cumulative dose-response curves and sensitivity to ACh in the (A) absence (control) or (B) presence of indomethacin in the aortae of CB+Placebo (●), STZ+Placebo (■) and STZ+RLX (▲) treated mice. (C) Basal NOS activity in the aortae of CB+Placebo, STZ+Placebo and STZ+RLX treated mice pre-contracted with U46619 to similar level before the addition of NOS inhibitor, L-NAME (200 μM). n = 5–6 per group. *pEC50/ Rmax significantly (P < 0.05) different to STZ+Placebo. #significantly (P = 0.0001) different to STZ+Placebo.